Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2023 11:17 ET | Source: Cancer Support Community

Cancer Support Community’s New Short Documentary Film Named Official Selection at CINEHEALTH International Health and Wellness Film and Video Festival

Washington D.C., Aug. 30, 2023 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC), a nonprofit organization dedicated to uplifting and strengthening all people impacted by cancer by providing...
June 14, 2022 10:00 ET | Source: Syapse

Syapse and Pierian Announce Genomics Collaboration to Power Precision Oncology

SAN FRANCISCO, June 14, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company announced with Pierian®, a global leader in advanced clinical genomics technology, a new joint...
August 07, 2018 08:55 ET | Source: AXIM BIOTECHNOLOGIES, INC

Axim® Biotechnologies Announces Positive Results From Stability And Dissolution Tests On Medchew Rx Showing Greater Than 90% Availability

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced positive results from...
January 23, 2018 09:00 ET | Source: AXIM BIOTECHNOLOGIES, INC

AXIM Biotech Announces Successful Completion of Exploratory Meeting with the Dutch Medicines Evaluation Board on MedChew Rx Program for Treatment of Pain and Spasticity in MS Patients

NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), the world leader in cannabinoid research and development, announced today that it has successfully completed an...
November 21, 2017 09:00 ET | Source: AXIM BIOTECHNOLOGIES, INC

Axim Biotechnologies Announces Phase IIa Trial Results Validating its Proprietary Cannabinoid Delivery Method for Treatment of Irritable Bowel Syndrome (IBS)

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results...
October 05, 2017 09:00 ET | Source: AXIM Biotechnologies, Inc

New U.S. Patent Allowance Granted to AXIM® Biotechnologies, Inc. for Cannabinoid Ophthalmic Solutions for Glaucoma and Conjunctivitis Treatment

NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech), (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the United States...
September 07, 2017 09:00 ET | Source: AXIM Biotechnologies, Inc

AXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York City

NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
August 22, 2017 09:00 ET | Source: AXIM Biotechnologies, Inc

AXIM Biotechnologies Reports Second Quarter 2017 Results

NEW YORK, Aug. 22, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter...
July 20, 2017 09:00 ET | Source: AXIM Biotechnologies, Inc

AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

NEW YORK, July 20, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a...
January 18, 2017 09:00 ET | Source: AXIM Biotechnologies, Inc

AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum

NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating...